Vertebral body defects treated with umbilical-cord mesenchymal stem cells combined with hydroxyapatite scaffolds: The ﬁrst case report

International Journal of Surgery Case Reports, 2020 · DOI: https://doi.org/10.1016/j.ijscr.2019.12.002 · Published: December 12, 2019

Surgery Orthopedics Regenerative Medicine & Stem Cells

Simple Explanation

This case report discusses the use of umbilical cord-derived mesenchymal stem cells (UC-MSCs) combined with hydroxyapatite scaffolds to treat vertebral body defects (VBDs). VBDs are common orthopedic issues that may require bone grafts or fusion, procedures that can sometimes fail. The patient, a 27-year-old female with a history of spinal tuberculosis and previous spinal surgery, experienced recurrent back pain. She underwent a procedure where the bone defect was filled with UC-MSCs and hydroxyapatite. After three months, the patient was able to walk without pain, and after six months, no complications were observed. This suggests that MSCs combined with hydroxyapatite may be a potential therapy for bone regeneration in VBDs.

Study Duration

6 Months

Participants

A 27-year-old female

Evidence Level

Level 4, Case Report

Key Findings

1
The patient could walk and had no pain three months post-surgery.
2
No complications occurred during the six-month follow-up period.
3
No signs of neoplasm formation or spinal cord compression were observed, suggesting the safety of the transplantation procedure.

Research Summary

This case report presents the successful treatment of a vertebral body defect (VBD) in a 27-year-old female using umbilical cord-derived mesenchymal stem cells (UC-MSCs) combined with hydroxyapatite scaffolds. The patient, who had a history of spinal tuberculosis and previous spinal surgery, experienced significant pain relief and improved mobility following the procedure. The study concludes that MSCs combined with hydroxyapatite represents a potential therapy for bone regeneration in VBD, warranting further clinical studies to investigate its safety and efficacy.

Practical Implications

Potential Therapeutic Strategy

MSCs combined with hydroxyapatite could offer a new approach for treating vertebral body defects.

Bone Regeneration

The study suggests that this combination can promote bone regeneration in VBDs.

Further Research

Clinical studies are needed to confirm the safety and efficacy of this therapy.

Study Limitations

1
Single case report limits generalizability.
2
Short follow-up period of six months.
3
Lack of a control group for comparison.

Your Feedback

Was this summary helpful?

Back to Surgery